Serif Biomedicines has announced preclinical data showing the potential of its Modified DNA as a new class of genetic medicines. 

Results from non-human primates, announced at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026, suggest Modified DNA could overcome barriers of innate immune activation and inefficient nuclear access. 

Following intravenous administration in non-human primates, lipid nanoparticle (LNP)-formulated Modified DNA was well-tolerated, with limited inflammation.  

Serif also showed that its proprietary mRNA co-factors dramatically increased gene expression from Modified DNA in hepatocytes and T cells in vitro and in vivo. 

“These results reflect the core elements we believe are required to support the development of Modified DNA as a new therapeutic modality, including reduction of innate immune activation, sustained expression, and demonstration of functional activity in vivo,” said Matt Kennedy, SVP, Head of Platform at Serif Biomedicines.  

“Together, they highlight Modified DNA’s potential to enable multiple categories of medicines for diseases where longer expression, cell-specific control, and the ability to dose again could create advantages over existing genetic medicine approaches.” 

Mirai Bio signals ‘enormous’ potential of nucleic acid medicines
 

Elsewhere at ASGCT 2026, Mirai Bio presented data demonstrating its platform optimises LNP delivery to adipocytes, reducing off-target delivery to the liver and spleen. 

Mirai believes the data could open a new extrahepatic frontier for nucleic acid medicines. 

The company’s adipocyte programme applies iterative in vivo machine learning optimisation across LNP components and composition, with the goal of increasing on-target white adipose tissue delivery while reducing off-target delivery to liver and spleen.  

In the data presented at ASGCT, Mirai screened more than 400 proprietary ionisable lipids for in vivo biodistribution and selected top-performing lipids for machine learning-guided optimisation. Using in vivo readouts, the platform identified optimised LNPs with distinct component and composition profiles that improved adipocyte delivery and selectivity. 

“Nucleic acid medicines have enormous therapeutic potential, but that potential is only realised when the right cargo reaches the right cells at the right level of activity,” said Jagesh Shah, SVP, Head of Platform at Mirai Bio.  

“These data show that delivery is not just an enabling step after cargo design; it is a core area of scientific innovation. By combining novel lipid chemistry, in vivo biodistribution data, and machine learning, Mirai is building a repeatable approach for multiparameter optimisation of LNPs against the delivery attributes that determine whether a nucleic acid medicine can advance.” 

Platform turns concept to proof-of-concept in 10 months

Mirai Bio also presented data at the Annual Meeting showing its platform can turn novel delivery designs into development programmes. 

The company claims it advanced a CD8-targeted LNP from concept to functional non-human primate proof-of-concept data in just 10 months. 

Two poster presentations highlighted how Mirai’s integrated platform addresses the core requirements for in vivo T-cell targeting, including T-cell specificity, reduced liver-directed delivery, scalable production, tolerability, and functional activity in relevant models, creating a cargo-ready foundation for partner programmes. 

“Nucleic acid medicine programmes can only move as fast as their delivery systems allow,” Shah added. 

“These data show that Mirai can help partners move from delivery concept to functional NHP proof-of-concept with the speed and translational relevance needed to make confident development decisions. For in vivo T-cell programmes, that means generating the proof points that matter, including functional activity, tolerability, and a clear path toward the clinic.”